Apollo Hospitals Enterprise Ltd vs Nephrocare Health Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Apollo Hospitals Enterprise Ltd is ₹ 7731 as of 23 Oct 15:30 . The P/E Ratio of Apollo Hospitals Enterprise Ltd changed from 277.5 on March 2021 to 55 on March 2026 . This represents a CAGR of -23.64% over 6 yearsThe P/E Ratio of Nephrocare Health Services Ltd changed from 66 on March 2026 to 66 on March 2026 . This represents a CAGR of 0.00% over 1 years The Market Cap of Apollo Hospitals Enterprise Ltd changed from ₹ 41739 crore on March 2021 to ₹ 106808 crore on March 2026 . This represents a CAGR of 16.95% over 6 yearsThe Market Cap of Nephrocare Health Services Ltd changed from ₹ 5072 crore on March 2026 to ₹ 5072 crore on March 2026 . This represents a CAGR of 0.00% over 1 years The revenue of Apollo Hospitals Enterprise Ltd for the Jun '26 is ₹ 7105 crore as compare to the Mar '26 revenue of ₹ 6659 crore. This represent the growth of 6.7% The revenue of Nephrocare Health Services Ltd for the Jun '26 is ₹ 289.21 crore as compare to the Mar '26 revenue of ₹ 277.18 crore. This represent the growth of 4.34% The ebitda of Apollo Hospitals Enterprise Ltd for the Jun '26 is ₹ 1154 crore as compare to the Mar '26 ebitda of ₹ 1065 crore. This represent the growth of 8.38% The ebitda of Nephrocare Health Services Ltd for the Jun '26 is ₹ 67.78 crore as compare to the Mar '26 ebitda of ₹ 62.24 crore. This represent the growth of 8.9% The net profit of Apollo Hospitals Enterprise Ltd changed from ₹ 315.5 crore to ₹ 610.4 crore over 9 quarters. This represents a CAGR of 34.09% The net profit of Nephrocare Health Services Ltd changed from ₹ 20.11 crore to ₹ 31.97 crore over 7 quarters. This represents a CAGR of 30.33% The Dividend Payout of Apollo Hospitals Enterprise Ltd changed from 41.09 % on March 2021 to 19.27 % on March 2026 . This represents a CAGR of -11.86% over 6 yearsThe Dividend Payout of Nephrocare Health Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Apollo Hospitals Enterprise Ltd

Apollo Hospitals Enterprise Limited (AHEL) is a leading private sector healthcare provider in Asia.
It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics.
AHEL's Hospitals are situated in Chennai, Hyderabad, Delhi, Ahmedabad, Pune, Chenganur, Coimbatore, Jaipur, Madurai, Anantpur, Nellore, Kurnool, Bhopal, Ranchi, Bilaspur and Bacheli.
The main business of the Company is to enhance the quality of life of patients by providing comprehensive, high-quality hospital services on a cost-effective basis and providing / selling high quality pharma and wellness products through a network of pharmacies.
The principal activities of the Company include operation of multidisciplinary private hospitals, clinics and pharmacies. Apollo Hospitals Enterprise Limited was incorporated as a Public Limited Company on December 5, 1979, a comprehensive 250-bed hospital with an emphasis on speciality and super specialties in over fifty departments at Chennai.

About Nephrocare Health Services Ltd

Nephrocare Health Services Limited was incorporated as 'Nephrocare Health Services Private Limited', a private limited company at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh on December 18, 2009.
Company was converted into a public limited company and the name was changed to 'Nephrocare Health Services Limited' with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. Company offer comprehensive dialysis care through a network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy.
The Company began journey in 2010 with the launch of its first dialysis clinic in Hyderabad.
It launched first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad in 2012; acquired 100% stake in DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd.

FAQs for the comparison of Apollo Hospitals Enterprise Ltd and Nephrocare Health Services Ltd

Which company has a larger market capitalization, Apollo Hospitals Enterprise Ltd or Nephrocare Health Services Ltd?

Market cap of Apollo Hospitals Enterprise Ltd is 111,173 Cr while Market cap of Nephrocare Health Services Ltd is 6,006 Cr

What are the key factors driving the stock performance of Apollo Hospitals Enterprise Ltd and Nephrocare Health Services Ltd?

The stock performance of Apollo Hospitals Enterprise Ltd and Nephrocare Health Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Apollo Hospitals Enterprise Ltd and Nephrocare Health Services Ltd?

As of October 25, 2026, the Apollo Hospitals Enterprise Ltd stock price is INR ₹7731.95. On the other hand, Nephrocare Health Services Ltd stock price is INR ₹597.3.

How do dividend payouts of Apollo Hospitals Enterprise Ltd and Nephrocare Health Services Ltd compare?

To compare the dividend payouts of Apollo Hospitals Enterprise Ltd and Nephrocare Health Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.